Overview

A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2029-10-01

Target enrollment:

Participant gender:

Summary

The study is a Phase II study to explore the efficacy and safety of SHR-A2102 in combination with other anti-tumor therapies as perioperative treatment in patients with resectable non-small cell lung cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Shanghai Hengrui Pharmaceutical Co., Ltd.

Treatments:

Carboplatin
osimertinib
Paclitaxel